IBDs (inflammatory bowel diseases) remain a complex issue, and the therapeutic approach is constantly changing and will continue to evolve during the future. Thus, descriptive and comparative studies based on real life experience of different therapeutic agents used in the treatments of IBDs are important in order to have a global assessment of the safety and side effects of those therapies. A retrospective analysis was conducted in this study and has included 112 patients with IBD, retrieved from a single center in Lebanon, in orderto assess the side effects in Lebanese IBD patients treated with different treatment regimens: biologic, immunosuppressors, or a combination of both drug classes. Side effects were mainly observed among IBD patients treated with azathioprines (31%) compared to 9% with the biologic treatment and 10% with the combination therapy. Side effects were mainly observed among smokers with Crohn’s disease as well as nonsmoker patients having Ulcerative Colitis. The side effects described in our study were mainly: Leucopenia, anemia, thrombocytopenia, hepatotoxicity, acute pancreatitis, Hodgkin Lymphoma, Non Hodgkin Lymphoma, cutaneous reaction, myalgia, infections and alopecia.
Impact Factor
2022: 6.012
This work is licensed under a